Small Biotech Focus Target Florida Biologix as a boutique preclinical and early-stage CDMO with specialized capabilities in cell line engineering, cGMP cell banking, and early process development to help accelerate partners in cell and gene therapy pipelines.

End-to-End CDMO Leverage their end-to-end service suite including vector/protein production in mammalian and insect cells, fill and finish, product testing, and regulatory support to position a comprehensive outsourcing option for mid-stage programs seeking reduced vendor handoffs.

Strategic Local Footprint Capitalize on Florida Biologix’s Alachua location and regional biotech ecosystem to propose nearby collaborations, symptomless supply chain resilience, and faster on-site onboarding for trials and regulatory filings.

Growth Leverage With revenue in the low millions and a recent merger history positioning them for scale, pitch bundled CDMO packages and strategic referrals to accelerate expansion into higher-value services and longer-term partnerships.

Tech & Compliance Edge Highlight their adoption of common enterprise tech and cGMP-compliant operations as a selling point for clients prioritizing robust data management, regulatory readiness, and scalable manufacturing as programs advance.